Full history for every metric is available with a Kvantra account
Plus Therapeutics, Inc. (PSTV)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 5 | 6 | 5 | 4 |
| Operating profit | $m | -15 | -26 | |||||
| Net profit | $m | -8 | -13 | -20 | -13 | -13 | -22 | -26 |
| EPS reported | $ | -7.19 | -4.41 | |||||
| Operating cashflow per share | $ | -6.68 | -3.27 | |||||
| Capex per share | $ | 0.02 | 0.20 | |||||
| FCF per share | $ | -6.70 | -3.48 | |||||
| Free cash flow | $m | -21 | -24 | |||||
| Net debt | $m | -8 | -9 | |||||
| Book value equity | $m | 4 | 5 | |||||
| Book value per share | $ | 1.28 | 0.81 | |||||
| Number of shares | m | 3.11 | 6.77 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 9.98 | 1.71 | |||||
| P/S LTM | x | 7.65 | 2.23 | |||||
| P/FCF LTM | x | -1.91 | -0.40 | |||||
| EV/EBITDA LTM | x | -1.74 | -0.03 | |||||
| EV/Sales LTM | x | 6.13 | 0.18 | |||||
| Earnings Yield LTM | % | -56.15% | -99.53% | |||||
| FCF Yield | % | -52.28% | -251.49% | |||||
| Quality | ||||||||
| ROE | % | -560.21% | -394.17% | |||||
| ROIC | % | -317.58% | -479.39% | |||||
| Operating margin | % | -293.46% | -628.12% | |||||
| Gross margin | % | 91.46% | 61.53% | |||||
| FCF/Sales | % | -399.81% | -560.29% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -10.49% | -20.95% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -25.39 | -535.20 | |||||
| Net Debt/EBITDA | x | 0.43 | 0.10 | |||||
| EBIT/Net interest | x | -4.24 | -8.56 | |||||
| Net debt/market cap | % | -19.91% | -91.70% | |||||
| Net debt/Equity | x | -1.99 | -1.57 | |||||
| Gross debt/equity | x | 0.21 | 0.01 | |||||
Company overview
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Plus Therapeutics, Inc. (PSTV)
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free